POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER).
Potassium chloride dissociates into potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse transmission, cardiac contractility, and acid-base balance. Replacement of potassium corrects hypokalemia.
| Metabolism | Potassium is not metabolized; it is primarily excreted renally (90%) via passive glomerular filtration and active secretion in the distal tubules. Minor losses occur via feces and sweat. |
| Excretion | Renal excretion is the primary route; >90% of potassium is excreted by the kidneys, with a small amount lost in feces (via gastrointestinal secretion) and negligible biliary excretion. Renal elimination is regulated by aldosterone and tubular secretion. |
| Half-life | Potassium chloride does not have a classic elimination half-life as it is an endogenous electrolyte. The terminal half-life of exogenous potassium is approximately 2-3 hours in healthy individuals, reflecting rapid cellular uptake and renal clearance. In renal impairment, half-life is prolonged. |
| Protein binding | Potassium is not significantly protein-bound; <1% is bound to plasma proteins. It exists primarily as free ions in plasma. |
| Volume of Distribution | Approximately 0.5-0.6 L/kg in adults, reflecting distribution into total body water. Potassium is predominantly intracellular; the apparent Vd is low due to rapid cellular uptake. Clinical meaning: a large Vd would indicate poor cellular uptake or loss from cells. |
| Bioavailability | Oral potassium chloride has a bioavailability of approximately 90-100% as it is well absorbed from the gastrointestinal tract. Intravenous potassium chloride has 100% bioavailability. |
| Onset of Action | Intravenous administration: immediate onset (within seconds to minutes) as potassium distributes into extracellular fluid. Oral administration: onset of action occurs within 1-2 hours, as absorption and cellular uptake take time. |
| Duration of Action | Intravenous: effect lasts as long as infusion continues and for a short period after (minutes to hours), depending on distribution and elimination. Oral: duration is several hours, typically 4-6 hours, depending on dose and renal function. |
| Molecular Weight | 74.55 |
20-40 mEq potassium chloride intravenously per dose, infused at a rate not exceeding 10 mEq/hour (or 20 mEq/hour in critical care settings), repeated as needed based on serum potassium levels. Maximum daily dose typically 200 mEq.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-59 mL/min: Administer with caution, reduce dose by 25-50% and monitor potassium closely. GFR <30 mL/min: Contraindicated or use only if severely deficient with extreme caution; reduce dose by at least 50% and avoid sustained release formulations. Hemodialysis: Use only with close monitoring; typical dose 10-20 mEq per session. |
| Liver impairment | Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 25% and monitor potassium. Child-Pugh C: Avoid use unless potassium severely deficient; reduce dose by at least 50% with frequent monitoring. |
| Pediatric use | Intravenous dose: 0.5-1 mEq/kg/dose, infused at a rate not exceeding 0.5-1 mEq/kg/hour, maximum single dose 20 mEq. For mild hypokalemia: 0.5-1 mEq/kg/day divided. For severe: up to 2 mEq/kg/day with monitoring. Not to exceed 1 mEq/kg/hour or 20 mEq/hour. |
| Geriatric use | Start at lower end of adult dosing (10-20 mEq) due to increased risk of hyperkalemia and renal impairment. Maximum infusion rate 10 mEq/hour. Use with caution and monitor potassium levels frequently; avoid potassium-sparing diuretics and ACE inhibitors. |
| 1st trimester | Potassium chloride is considered safe and essential in pregnancy for treating hypokalemia when guided by serum levels. However, hyperkalemia must be avoided as it may cause fetal arrhythmias. Use only if clearly needed. |
| 2nd trimester | Same as first trimester: safe when used for potassium replacement under monitoring. Avoid hyperkalemia. |
| 3rd trimester | Same as first and second trimesters. Close monitoring of maternal serum potassium is recommended to prevent hyperkalemia, which can affect uterine contractions and fetal heart rate. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER).
| Placental transfer | Potassium crosses the placenta via active transport and passive diffusion, maintaining fetal serum levels slightly higher than maternal. Placental transfer is regulated to maintain fetal homeostasis. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk; supplementation is unlikely to affect infant serum potassium levels at usual maternal doses. However, monitor maternal serum potassium to avoid excessive levels that could theoretically be secreted into milk. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | No evidence of teratogenicity in first trimester. Physiological potassium homeostasis is critical; severe maternal hypokalemia may increase risk of fetal adverse effects. No dose-limiting fetal toxicity reported. |
| Fetal Monitoring | Monitor maternal serum potassium, renal function, and ECG for signs of hyperkalemia (peaked T waves, arrhythmias). Monitor fetal heart rate during intravenous administration if clinically indicated. |
| Fertility Effects | No known direct effects on fertility. Correcting hypokalemia may improve any underlying condition-associated reproductive dysfunction. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use. Rapid infusion or high concentrations may cause fatal hyperkalemia, cardiac arrest, or arrhythmias. Intravenous administration must be via a large-bore vein with continuous cardiac monitoring.
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaConcurrent use of potassium-sparing diuretics (e.g., spironolactone) unless closely monitoredAcute dehydrationAdrenal insufficiency (untreated Addison's disease)Potassium-sensitive familial periodic paralysisConditions predisposing to hyperkalemia (e.g., severe hemolytic reactions, extensive tissue necrosis)
| Precautions | Risk of hyperkalemia in renal impairment, Avoid in severe renal failure with oliguria, Monitor serum potassium and ECG during IV administration, Use with caution in patients with cardiac disease, adrenal insufficiency, or metabolic acidosis, Extravasation may cause tissue necrosis |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados, legumes, salt substitutes containing potassium) while on potassium therapy to prevent hyperkalemia. Consult dietitian for balanced intake. |
| Clinical Pearls | Potassium chloride 10 mEq in plastic container (typically 100 mL volume) is used for correction of hypokalemia. Administer via peripheral or central line; for peripheral infusion, rates should not exceed 10 mEq/hour and concentration should not exceed 40 mEq/L to avoid phlebitis. In critical care, may use higher concentrations via central line with cardiac monitoring. Always assess renal function before administration; do not give in severe renal impairment or hyperkalemia. Potassium is irritating to veins; ensure proper IV site rotation. |
| Patient Advice | Report any burning or pain at the IV site immediately. · Do not stop or adjust the infusion rate; the nurse will manage it. · Inform your doctor if you have kidney problems or are taking medications that increase potassium (e.g., ACE inhibitors, spironolactone). · Symptoms of too much potassium include muscle weakness, irregular heartbeat, or numbness/tingling. · This medication is replacing potassium lost from your body; it is important to follow dietary potassium guidance. |
Loading safety data…